Case Study: Navigating the preclinical “Valley of Death”- Scaling from Discovery to Tox Batch

A virtual biotechnology company with a pipeline of novel oncology targets had successfully identified a promising lead candidate from its internal Lead Optimisation (LO) programme. The compound, a highly selective small molecule, demonstrated excellent in vitro efficacy and a favourable early ADME profile, making it a priority for preclinical development.